These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 3142665)
1. A comparison of the pharmacokinetics of 14C-labelled APD and 99mTc-labelled APD in the mouse. Daley-Yates PT; Bennett R Calcif Tissue Int; 1988 Aug; 43(2):125-7. PubMed ID: 3142665 [TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics and distribution of pamidronate for a range of doses in the mouse. Hoggarth CR; Bennett R; Daley-Yates PT Calcif Tissue Int; 1991 Dec; 49(6):416-20. PubMed ID: 1818767 [TBL] [Abstract][Full Text] [Related]
3. Is (99m)Tc-labelled pamidronate a better agent than (99m)Tc-medronate for bone imaging? Kumar V; Kumar D; Howman-Giles RB; Little DG Nucl Med Commun; 2007 Feb; 28(2):101-7. PubMed ID: 17198350 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the pharmacokinetics of 14C-labelled APD and 99mTc-labelled APD in the mouse. Fogelman I; Lazarus C Calcif Tissue Int; 1989 Sep; 45(3):198-9. PubMed ID: 2505912 [No Abstract] [Full Text] [Related]
5. Biodistribution studies of the 186Re complex of 3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid in mice. Alyafei S; Tomiyoshi K; Sarwar M; Ahmed K; Zhang H; Oriuchi N; Inoue T; Endo K Nucl Med Commun; 1999 Jun; 20(6):551-7. PubMed ID: 10451868 [TBL] [Abstract][Full Text] [Related]
6. Technetium-99m complexes of dimethylaminomethylene diphosphonate (DMAD)--II. Biological distributions of 99mTc-DMAD components isolated by anion exchange HPLC. Holland ME; Bugaj J; Heineman WR; Deutsch E Int J Rad Appl Instrum B; 1989; 16(3):313-7. PubMed ID: 2497091 [TBL] [Abstract][Full Text] [Related]
7. Disposition and nephrotoxicity of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD), in rats and mice. Cal JC; Daley-Yates PT Toxicology; 1990 Dec; 65(1-2):179-97. PubMed ID: 1980383 [TBL] [Abstract][Full Text] [Related]
8. Retention of technetium-99m in infectious foci in rats after release from technetium-99m labelled human non-specific polyclonal immunoglobulin G: a dual-label study with hydrazinonicotinamido and iminothiolano immunoglobulin. Claessens RA; Koenders EB; Oyen WJ; Corstens FH Eur J Nucl Med; 1996 Nov; 23(11):1536-9. PubMed ID: 8854855 [TBL] [Abstract][Full Text] [Related]
9. Technetium-99m APD compared with technetium-99m MDP as a bone scanning agent. Degrossi OJ; Oliveri P; García del Río H; Labriola R; Artagaveytía D; Degrossi EB J Nucl Med; 1985 Oct; 26(10):1135-9. PubMed ID: 4045556 [TBL] [Abstract][Full Text] [Related]
10. The influence of the charge and of the tin-ligand ratio on bone uptake of technetium 99m labelled osteotropic radiopharmaceuticals. Gouaillardou D; Conti ML Int J Rad Appl Instrum A; 1987; 38(2):103-6. PubMed ID: 3032858 [TBL] [Abstract][Full Text] [Related]
11. Technetium-1,2-dihydroxy-1,2-bis(dihydroxyphosphinyl)ethane (99mTc-DHPE). A promising new skeletal imaging agent. Archimandritis SC; Tsolis AK Eur J Nucl Med; 1987; 13(3):134-8. PubMed ID: 3622557 [TBL] [Abstract][Full Text] [Related]
12. Clearance and tissue uptake following 4-hour and 24-hour infusions of pamidronate in rats. Pongchaidecha M; Daley-Yates PT Drug Metab Dispos; 1993; 21(1):100-4. PubMed ID: 8095201 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of the osteotropic diphosphonate 3-amino-1-hydroxypropane-1,1-diphosphonic acid in mammals. Wingen F; Schmähl D Arzneimittelforschung; 1987 Sep; 37(9):1037-42. PubMed ID: 3435598 [TBL] [Abstract][Full Text] [Related]
14. Technetium-99m labelled hydrazinonicotinamido human non-specific polyclonal immunoglobulin G for detection of infectious foci: a comparison with two other technetium-labelled immunoglobulin preparations. Claessens RA; Boerman OC; Koenders EB; Oyen WJ; van der Meer JW; Corstens FH Eur J Nucl Med; 1996 Apr; 23(4):414-21. PubMed ID: 8612662 [TBL] [Abstract][Full Text] [Related]
15. Technetium 99m labelled heparin: pharmacokinetics and tissue distribution in rats after vascular surgery. Colas-Linhart N; Berthelot JL; Ducret A; Petiet A; Bok B Biomed Pharmacother; 1987; 41(4):189-91. PubMed ID: 3620586 [TBL] [Abstract][Full Text] [Related]
16. Serum kinetics, bioavailability and bone scanning of 99mTc-labelled sodium olpadronate in patients with different rates of bone turnover. Degrossi OJ; Ortiz M; Degrossi EB; García del Río H; Barreira JC; Messina D; Kerzberg E; Roldán EJ; Montuori E; Pérez Lloret A Eur J Clin Pharmacol; 1995; 48(6):489-94. PubMed ID: 8582468 [TBL] [Abstract][Full Text] [Related]
17. Complexes of technetium-99m with tetrapeptides containing one alanyl and three glycyl moieties. Vanbilloen HP; De Roo MJ; Verbruggen AM Eur J Nucl Med; 1996 Jan; 23(1):40-8. PubMed ID: 8586100 [TBL] [Abstract][Full Text] [Related]
18. Chemical and biological evaluation of technetium (I) tricarbonyl complexes with EHIDA and DPD. 99m (I) complexes of EHIDA and DPD. Djokić DDj; Janković DLj; Stamenković LLj; Pirmettis I Nucl Med Rev Cent East Eur; 2004; 7(1):1-5. PubMed ID: 15318303 [TBL] [Abstract][Full Text] [Related]
19. Elimination and clearance of pamidronate by haemodialysis. Buttazzoni M; Rosa Diez GJ; Jager V; Crucelegui MS; Algranati SL; Plantalech L Nephrology (Carlton); 2006 Jun; 11(3):197-200. PubMed ID: 16756631 [TBL] [Abstract][Full Text] [Related]
20. 99mTc(CO)3-labeled pamidronate and alendronate for bone imaging. Palma E; Correia JD; Oliveira BL; Gano L; Santos IC; Santos I Dalton Trans; 2011 Mar; 40(12):2787-96. PubMed ID: 21301703 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]